ICIs currently used in the treatment of ccRCC mainly include pembrolizumab and nivolumab (PD-1 suppressants); avelumab and atezolizumab (PD-L1 suppressants); and ipilimumab (CTLA-4 suppressant). The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.